Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M11,103Revenue $M1,134Net Margin (%)-36.6Z-Score1.3
Enterprise Value $M13,424EPS $-6.5Operating Margin %-43.2F-Score4
P/E(ttm))0Cash Flow Per Share $3.6Pre-tax Margin (%)-58.5Higher ROA y-yN
Price/Book46.310-y EBITDA Growth Rate %0Quick Ratio0.6Cash flow > EarningsY
Price/Sales9.75-y EBITDA Growth Rate %0Current Ratio0.7Lower Leverage y-yY
Price/Cash Flow11.8y-y EBITDA Growth Rate %-195.1ROA % (ttm)-9.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-71.0Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M63.7ROI % (ttm)2.6Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPJohn Paulson 2014-12-31 Buy 3.4%$91.47 - $152.87
($120.33)
$ 172.8130%New holding5,806,000
SLXPGeorge Soros 2014-12-31 Buy 0.62%$91.47 - $152.87
($120.33)
$ 172.8130%New holding491,531
SLXPAndreas Halvorsen 2014-12-31 Reduce-0.61%$91.47 - $152.87
($120.33)
$ 172.8130%Reduce -36.09%1,738,104
SLXPVanguard Health Care Fund 2014-12-31 Sold Out -0.61%$91.47 - $152.87
($120.73)
$ 172.8130%Sold Out0
SLXPVanguard Health Care Fund 2014-09-30 Reduce-0.09%$127.75 - $169.17
($144.97)
$ 172.8116%Reduce -15.70%1,538,045
SLXPAndreas Halvorsen 2014-09-30 Reduce-0.09%$127.75 - $169.17
($144.97)
$ 172.8116%Reduce -5.88%2,719,538
SLXPAndreas Halvorsen 2014-06-30 Add0.74%$97.7 - $125.07
($110.33)
$ 172.8136%Add 86.19%2,889,303
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 172.8136%Sold Out0
SLXPVanguard Health Care Fund 2014-06-30 Reduce-0.06%$97.7 - $125.07
($110.42)
$ 172.8136%Reduce -10.25%1,824,545
SLXPAndreas Halvorsen 2014-03-31 Buy 0.67%$88.8 - $114.64
($101.95)
$ 172.8141%New holding1,551,766
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 172.8141%New holding307,445
SLXPVanguard Health Care Fund 2014-03-31 Reduce-0.03%$89.09 - $114.64
($102.39)
$ 172.8141%Reduce -5.36%2,032,845
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 172.8160%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 172.8167%New holding127,495
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 172.8172%Sold Out0
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 172.8172%Add 22.44%2,147,945
SLXPNWQ Managers 2012-12-31 Sold Out -0.17%$37.97 - $42.9
($40.82)
$ 172.8176%Sold Out0
SLXPJoel Greenblatt 2012-12-31 Add0.06%$37.97 - $42.9
($40.82)
$ 172.8176%Add 75.81%63,399
SLXPVanguard Health Care Fund 2012-12-31 Add0.02%$37.97 - $42.9
($40.81)
$ 172.8176%Add 12.87%1,754,300
SLXPJoel Greenblatt 2012-09-30 Buy 0.1%$41.92 - $55.65
($47.44)
$ 172.8173%New holding36,061
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Forbes William PPresident, Medical R&D and CDO 2015-03-09Sell42,880$157.849.37view
Forbes William PEVP Research&Devel & CDO 2015-03-06Sell20,000$157.969.29view
Scruggs Rick DExecutive Vice President 2015-03-06Sell4,000$157.559.57view
CREECH TIMOTHY JSee Remarks 2015-03-06Sell4,600$157.679.49view
Forbes William PEVP Research&Devel & CDO 2014-11-12Sell11,079$95.0581.62view
CREECH TIMOTHY JSee Remarks 2014-11-05Sell0$081.62view
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.3839.92view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6763.37view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8955.68view
Scruggs Rick DExecutive Vice President 2014-03-04Sell1,319$110.6656view

Press Releases about SLXP :

    Quarterly/Annual Reports about SLXP:

    News about SLXP:

    Articles On GuruFocus.com
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 
    Looking Ahead of Wall Street: Salix Pharmaceuticals, Receptos, Tetraphase Mar 02 2015 
    Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
    John Paulson's Top Buys Feb 22 2015 
    John Paulson Chooses Energy, Semiconductor and Drug Stocks in Q4 Feb 20 2015 
    Fourth-Quarter Acquisitions Rearrange Jana Partners’ Portfolio Feb 18 2015 
    Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 
    SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceu Dec 13 2014 


    More From Other Websites
    Synergy Pharma exploring sale - Bloomberg Mar 26 2015
    4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary Mar 25 2015
    Salix had a $13B offer on the table before accounting problems crashed share price Mar 24 2015
    Novartis Reports Positive Data on Psoriasis Drug Cosentyx - Analyst Blog Mar 23 2015
    Eminence Capital Downs Position in Valeant Pharmaceuticals Mar 23 2015
    AstraZeneca, Daiichi Sankyo to Co-Market Movantik in U.S. - Analyst Blog Mar 20 2015
    Tetraphase Closes Public Offering, to Raise $173.1M - Analyst Blog Mar 19 2015
    Salix execs – including two that resigned – to receive $78M in golden parachutes Mar 19 2015
    Pharming Nominates Paul Sekhri and Jan Egberts as Members of its Board of Supervisory Directors Mar 19 2015
    Valeant (VRX) Prices Shares to Finance Salix Acquisition - Analyst Blog Mar 18 2015
    Salix's New Deal Yields More Fees for J.P. Morgan, Centerview Mar 18 2015
    Salix Executives Who Left After Financial Errors Get $46 Million Mar 18 2015
    How Salix's Executives Got Paid Millions Even After Quitting Mar 18 2015
    The Zacks Analyst Blog Highlights: Valeant Pharmaceuticals International, Salix Pharmaceuticals,... Mar 18 2015
    Obama crackdown fails to stop foreign mergers Mar 17 2015
    Ruthigen-Pulmatrix Merge, Focus on Respiratory Drugs - Analyst Blog Mar 17 2015
    Valeant (VRX) Raises Salix Offer, Endo Withdraws Proposal - Analyst Blog Mar 17 2015
    Valeant Bonds Trade Higher, Despite Skepticism Mar 17 2015
    Valeant Bumps Its Offer to $173 to Seal the Salix Deal Mar 17 2015
    Overheard: Valeant’s High-Cost M&A Treatment Mar 16 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK